JAK mutations in high-risk childhood acute lymphoblastic leukemia

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 23, 2009, Pages 9414-9418

  Mullighan, Charles G ^a   Zhang, Jinghui ^b   Harvey, Richard C ^c   Collins Underwood, J Racquel ^a   Schulman, Brenda A ^a   Phillips, Letha A ^a   Tasian, Sarah K ^d   Loh, Mignon L ^d   Su, Xiaoping ^a   Liu, Wei ^a   Devidas, Meenakshi ^e   Atlas, Susan R ^c,f   Chen, I Ming ^c   Clifford, Robert J ^b   Gerhard, Daniela S ^b   Carroll, William L ^g   Reaman, Gregory H ^h   Smith, Malcolm ^b   Downing, James R ^a   Hunger, Stephen P ⁱ   Willman, Cheryl L ^c   more..

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF NEW MEXICO   (United States)

^g NEW YORK UNIVERSITY   (United States)

^h GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

ⁱ UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

IKAROS; Kinase; Mutation

Indexed keywords

BCR ABL PROTEIN; CYCLINE; GROWTH FACTOR; IKAROS TRANSCRIPTION FACTOR; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; PROTEIN TYROSINE KINASE; STAT PROTEIN; STAT5 PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ARTICLE; BCR ABL1 GENE; CDKN2A GENE; CDKN2B GENE; CHILDHOOD LEUKEMIA; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; CONTROLLED STUDY; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENETIC CONSERVATION; HIGH RISK POPULATION; HUMAN; IKZF1 GENE; JAK GENE; JAK1 GENE; JAK2 GENE; JAK3 GENE; MOUSE; NONHUMAN; ONCOGENE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; SIGNAL TRANSDUCTION;

CHILD; GENE EXPRESSION PROFILING; HUMANS; IKAROS TRANSCRIPTION FACTOR; JANUS KINASE 1; JANUS KINASE 3; JANUS KINASES; MUTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SIGNAL TRANSDUCTION;

EID: 67249146555     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0811761106     Document Type: Article

References (33)

1. Pui CH, Robison LL, Look AT (2008) Acute lymphoblastic leukaemia. Lancet 371:1030-1043.
2. Mullighan CG, et al. (2007) Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446:758-764. (Pubitemid 46582031)
3. Mullighan CG, et al. (2008) BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453:110-114. (Pubitemid 351630327)
4. Mullighan CG, et al. (2009) Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 360:470-480.
5. Nachman JB, et al. (1998) Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 338:1663-1671. (Pubitemid 28267911)
6. Borowitz MJ, et al. (2008) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: A Children's Oncology Group study. Blood 111:5477-5485.
7. Samanta AK, et al. (2006) Janus kinase 2: A critical target in chronic myelogenous leukemia. Cancer Res 66:6468-6472. (Pubitemid 44085597)
8. Xie S, et al. (2001) Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene 20:6188-6195. (Pubitemid 32964431)
9. Vainchenker W, Dusa A, Constantinescu SN (2008) JAKs in pathology: Role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol 19:385-393.
10. Bercovich D, et al. (2008) Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 372:1484-1492.
11. Kearney L, et al. (2008) A specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood 113:646-648.
12. Flex E, et al. (2008) Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med 205:751-758. (Pubitemid 351549874)
13. James C, et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144-1148. (Pubitemid 40663494)
14. Kralovics R, et al. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779-1790. (Pubitemid 40570926)
15. Levine RL, et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387-397. (Pubitemid 40544655)
16. Baxter EJ, et al. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054-1061. (Pubitemid 40386783)
17. Staerk J, et al. (2005) JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: Cross-talk with IGF1 receptor. J Biol Chem 280:41893-41899. (Pubitemid 43023158)
18. Saharinen P, Silvennoinen O (2002) The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem 277:47954-47963. (Pubitemid 36159324)
19. Russo AA, et al. (1996) Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 382:325-331. (Pubitemid 26260452)
20. Russo AA, et al. (1998) Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature 395:237-243. (Pubitemid 28447541)
21. Brotherton DH, et al. (1998) Crystal structure of the complex of the cyclin D-dependent kinase Cdk6 bound to the cell-cycle inhibitor p19INK4d. Nature 395:244-250. (Pubitemid 28447542)
22. Lucet IS, et al. (2006) The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 107:176-183. (Pubitemid 43053540)
23. Levine RL, Pardanani A, Tefferi A, Gilliland DG (2007) Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 7:673-683. (Pubitemid 47327415)
24. Levine RL, Gilliland DG (2008) Myeloproliferative disorders. Blood 112:2190-2198.
25. Shuster JJ, et al. (1999) Identification of newly diagnosed children with acute lymphocytic leukemia at high risk for relapse. Cancer Res Ther Control 9:101-107. (Pubitemid 29408333)
26. Funakoshi-Tago M, et al. (2008) Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity. Mol Cell Biol 28:1792-1801.
27. Kotecha N, et al. (2008) Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell 14:335-343.
28. Subramanian A, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102:15545-15550. (Pubitemid 41528093)
29. Yeoh EJ, et al. (2002) Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1:133-143. (Pubitemid 41039160)
30. Ross ME, et al. (2003) Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 102:2951-2959. (Pubitemid 37248870)
31. Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154.
32. Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170.
33. Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509